Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BaselineVariablesList
.... 14.5 BookCitation
.... 14.6 BookPartCitation
.... 14.7 CertaintyOfEvidence
.... 14.8 Classification
.... 14.9 CohortDefinition
.... 14.10 Comment
.... 14.11 ComparativeBaselineMeasureEvidence
.... 14.12 ComparativeEvidence
.... 14.13 ComparativeEvidenceReport
.... 14.14 ComparativeEvidenceReportExpanded
.... 14.15 ComparativeEvidenceReportSubject
.... 14.16 ComparativeEvidenceSynthesisReport
.... 14.17 ComparativeParticipantFlowEvidence
.... 14.18 ComparatorGroup
.... 14.19 ComparatorOnlyEvidence
.... 14.20 Comparison
.... 14.21 CompositeRating
.... 14.22 ConceptualCohortDefinition
.... 14.23 ConceptualComparatorDefinition
.... 14.24 ConceptualExposureDefinition
.... 14.25 DatabaseCitation
.... 14.26 DatabaseEntryCitation
.... 14.27 DatasetCitation
.... 14.28 DateAsRating
.... 14.29 DichotomousIntendedOutcome
.... 14.30 EndpointAnalysisPlan
.... 14.31 EvidenceAssessment
.... 14.32 EvidenceList
.... 14.33 EvidenceReport
.... 14.34 EvidenceReportPackage
.... 14.35 EvidenceReportSubject
.... 14.36 EvidenceSynthesisEvidence
.... 14.37 ExposureGroup
.... 14.38 GroupAssignment
.... 14.39 GroupR6
.... 14.40 Guideline
.... 14.41 InterventionOnlyEvidence
.... 14.42 JournalArticleCitation
.... 14.43 M11Report
.... 14.44 MetaanalysisEligibilityCriteria
.... 14.45 MetaanalysisOutcomeDefinition
.... 14.46 MetaanalysisStudyGroup
.... 14.47 NetEffectContribution
.... 14.48 NetEffectContributionList
.... 14.49 NetEffectContributions
.... 14.50 NetEffectEstimate
.... 14.51 NonComparativeEvidence
.... 14.52 OutcomeDefinition
.... 14.53 OutcomeImportance
.... 14.54 OutcomeList
.... 14.55 OutcomeMeasureReport
.... 14.56 OutcomeVariablesList
.... 14.57 ParticipantFlowEvidence
.... 14.58 ParticipantFlowEvidenceVariable
.... 14.59 ParticipantFlowReasonEvidenceVariable
.... 14.60 ParticipantFlowReport
.... 14.61 ParticipantFlowVariablesList
.... 14.62 PreprintCitation
.... 14.63 Rating
.... 14.64 Recommendation
.... 14.65 RecommendationAction
.... 14.66 RecommendationEligibilityCriteria
.... 14.67 RecommendationJustification
.... 14.68 RecommendationPlan
.... 14.69 RecommendationRating
.... 14.70 ResearchStudyDataDictionary
.... 14.71 ResearchStudySupport
.... 14.72 RiskOfBias
.... 14.73 SearchResults
.... 14.74 SearchStrategy
.... 14.75 SingleStudyEvidence
.... 14.76 SoaPlanDefinition
.... 14.77 SoftwareCitation
.... 14.78 StatisticModel
.... 14.79 StudyDesign
.... 14.80 StudyEligibilityCriteria
.... 14.81 StudyGroup
.... 14.82 StudyRegistryRecord
.... 14.83 SummaryOfFindings
.... 14.84 SummaryOfNetEffect
.... 14.85 SystematicReview
.... 14.86 SystematicReviewEligibilityCriteria
.... 14.87 SystematicReviewExcludedStudies
.... 14.88 SystematicReviewIncludedStudies
.... 14.89 VariableDefinition
.... 14.90 WebPageCitation
.... 14.91 AdditionalLanguage
.... 14.92 ArtifactAssessmentCompared
.... 14.93 ArtifactAssessmentDateAsRating
.... 14.94 ArtifactPublicationStatus
.... 14.95 CharacteristicTiming
.... 14.96 CiteAs
.... 14.97 CompositionExtendedContactDetail
.... 14.98 EvidenceVariableHandlingDetail
.... 14.99 GuidelineRegistration
.... 14.100 NumberAnalyzed
.... 14.101 PublicationDate
.... 14.102 RelatesTo
.... 14.103 RelatesToClassifier
.... 14.104 RelatesToWithQuotation
.... 14.105 RelativeOutcomeImportance
.... 14.106 ResearchStudyExcludedStudy
.... 14.107 ResearchStudyIncludedStudy
.... 14.108 ResearchStudyIsLowInterventionTrial
.... 14.109 ResearchStudyNumberOfStudiesIdentified
.... 14.110 ResearchStudyNumberOfStudiesIncluded
.... 14.111 ResearchStudySaeReportingMethod
.... 14.112 ResearchStudySearchStrategy
.... 14.113 ResearchStudySponsorConfidentialityStatement
.... 14.114 ResearchStudyStudyAmendment
.... 14.115 ResearchStudySystematicReviewEligibilityCriteria
.... 14.116 StatisticModelExpression
.... 14.117 StatisticModelIncludeIf
.... 14.118 EBMonFHIR Profile Name Value Set
.... 14.119 Evidence Rating System Classifier Codes Value Set
.... 14.120 Recommendation Justification Classifier Codes Value Set
.... 14.121 Research Study Document Types Value Set
.... 14.122 Search Strategy Characteristic Value Set
.... 14.123 EBMonFHIR Profile Name Code System
.... 14.124 Evidence Rating System Classifier Code System
.... 14.125 Research Study Document Types Code System
.... 14.126 Search Strategy Characteristic Code System
.... 14.127 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.128 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.129 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.130 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.131 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.132 179899
.... 14.133 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.134 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.135 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.136 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.137 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.138 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.139 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.140 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.141 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.142 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.143 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.144 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.145 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.146 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.147 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.148 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.149 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.150 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.151 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.152 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.153 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.154 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.155 27979893 6. Glycemic Targets.
.... 14.156 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.157 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.158 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.159 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.160 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.161 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.162 30467172 Finding my inner Wonder Woman.
.... 14.163 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.164 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.165 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.166 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.167 367832
.... 14.168 367833
.... 14.169 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.170 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.171 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.172 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.173 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.174 Add-on Amlodipine at 6 weeks
.... 14.175 Adults with diabetes mellitus type 2
.... 14.176 Adults with diabetes type 2 and established CVD (but no CKD)
.... 14.177 Adults with type 2 diabetes, CVD and CKD
.... 14.178 Adverse event free and hypertension control
.... 14.179 Adverse event free and hypertension control at 12 weeks
.... 14.180 Adverse Events Report for NCT03640312
.... 14.181 Age
.... 14.182 Age with comparator
.... 14.183 Age with intervention
.... 14.184 Aircraft Type
.... 14.185 Aircraft Type with comparator
.... 14.186 Aircraft Type with intervention
.... 14.187 Altitude
.... 14.188 Altitude comparing intervention vs. comparator
.... 14.189 Altitude for enrolled group
.... 14.190 Altitude for screened group
.... 14.191 Altitude with comparator
.... 14.192 Altitude with intervention
.... 14.193 Analyzed Group in PARACHUTE Trial
.... 14.194 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.195 Baseline Characteristics Report for NCT03640312
.... 14.196 Baseline Characteristics Report for QUARTET Trial
.... 14.197 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.198 Baseline Measures List for PARACHUTE Trial
.... 14.199 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.200 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.201 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.202 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.203 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.204 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.205 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.206 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.207 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.208 Candesartan 8 mg once daily
.... 14.209 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.210 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.211 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.212 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.213 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.214 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.215 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.216 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.217 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.218 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.219 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.220 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.221 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.222 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.223 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.224 Citation for EBMonFHIR Implementation Guide
.... 14.225 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.226 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.227 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.228 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.229 Comparative Evidence Report for QUARTET USA Trial
.... 14.230 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.231 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.232 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.233 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.234 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.235 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.236 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.237 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.238 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.239 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.240 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.241 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.242 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.243 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.244 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.245 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.254 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.255 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.256 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.257 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.258 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.259 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.260 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.261 ComparatorDefinition: Standard care
.... 14.262 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.263 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.264 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.265 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.266 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.267 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.268 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.269 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.270 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.271 Computable_Publishing_LLC
.... 14.272 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.273 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.274 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.275 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.276 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.277 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.278 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.279 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.280 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.281 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.282 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.283 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.284 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.285 ConceptualCohortDefinition: Nonfatal stroke
.... 14.286 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.287 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.288 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.289 ConceptualCohortDefinition: Severe obesity
.... 14.290 ConceptualCohortDefinition: T1DM or T2DM
.... 14.291 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.292 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.293 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.294 ConceptualCohortDefinition_Cardiovascular_event
.... 14.295 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.296 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.297 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.298 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.299 COVID_19PneumoniaHospitalizedAdult
.... 14.300 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.301 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.302 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.303 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.304 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.305 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.306 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.307 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.308 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.309 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.310 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.311 DatabaseCitation: Citation for FEvIR Platform
.... 14.312 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.313 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.314 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.315 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.316 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.317 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.318 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.319 declined randomization in PARACHUTE Study
.... 14.320 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.321 Delany-Moretlwe 2022 clinical trial
.... 14.322 Diabetes treatment medication
.... 14.323 Diastolic blood pressure at 12 weeks
.... 14.324 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.325 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.326 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.327 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 14.328 Eligibility criteria for NMA_Diabetes
.... 14.329 Eligibility Criteria for QUARTET USA Trial
.... 14.330 Enrolled Group for QUARTET USA Trial
.... 14.331 Enrolled Group PARACHUTE Trial
.... 14.332 Ethnic Group
.... 14.333 Ethnic Group with comparator
.... 14.334 Ethnic Group with intervention
.... 14.335 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.336 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.337 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.338 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.339 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.340 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.341 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.342 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.343 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.344 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.345 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.346 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.347 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.348 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.349 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.350 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.351 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.352 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.353 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.354 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.355 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.356 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.357 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.358 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.359 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.360 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.361 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.362 EvidenceReportSectionCode Value Set
.... 14.363 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.364 EvidenceVariable Handling Extension Value Set
.... 14.365 EvidenceVariable: case_id
.... 14.366 EvidenceVariable: Patient id
.... 14.367 EvidenceVariable: Time of measurement
.... 14.368 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.369 Excluded from PARACHUTE Study
.... 14.370 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.371 ExposureVariable: Age (as continuous variable)
.... 14.372 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.373 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.374 ExposureVariable: pht013093.v1.p1 RACE
.... 14.375 ExposureVariable: pht013093.v1.p1 SEX
.... 14.376 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.377 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.378 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.379 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.380 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.381 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.382 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.383 Family History of Parachute Use
.... 14.384 Family History of Parachute Use with comparator
.... 14.385 Family History of Parachute Use with intervention
.... 14.386 Frequent Flier
.... 14.387 Frequent Flier with comparator
.... 14.388 Frequent Flier with intervention
.... 14.389 GLP-1 RA Group in Adults with diabetes type 2 with moderate CV risk
.... 14.390 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.391 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.392 Glucagon Nasal Powder (Experimental)
.... 14.393 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.394 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.395 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.396 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.397 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.398 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.399 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.400 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.401 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.402 GroupAssignment: Quadpill vs. Candesartan
.... 14.403 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.404 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.405 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.406 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.407 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.408 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.409 Health Survey Score Total
.... 14.410 Health Survey Score Total comparing intervention vs. comparator
.... 14.411 Health Survey Score Total with comparator
.... 14.412 Health Survey Score Total with intervention
.... 14.413 Health Survey Score-Mental Health Subscore
.... 14.414 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.415 Health Survey Score-Mental Health Subscore with comparator
.... 14.416 Health Survey Score-Mental Health Subscore with intervention
.... 14.417 Health Survey Score-Physical Health Subscore
.... 14.418 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.419 Health Survey Score-Physical Health Subscore with comparator
.... 14.420 Health Survey Score-Physical Health Subscore with intervention
.... 14.421 Health-related Quality of Life (NCT03640312)
.... 14.422 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.423 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.424 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.425 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.426 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.427 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.428 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.429 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.430 Height
.... 14.431 Height with comparator
.... 14.432 Height with intervention
.... 14.433 High Blood Pressure Medication Value Set
.... 14.434 History of Acrophobia
.... 14.435 History of Acrophobia with comparator
.... 14.436 History of Acrophobia with intervention
.... 14.437 History of Broken Bones
.... 14.438 History of Broken Bones with comparator
.... 14.439 History of Broken Bones with intervention
.... 14.440 History of Parachute Use
.... 14.441 History of Parachute Use with comparator
.... 14.442 History of Parachute Use with intervention
.... 14.443 Hypertension Control at 12 weeks
.... 14.444 ICD-10-GM Terminale Codes
.... 14.445 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.446 Injury Severity Score 30 days after Impact with comparator
.... 14.447 Injury Severity Score 30 days after Impact with intervention
.... 14.448 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.449 Injury Severity Score on Impact with comparator
.... 14.450 Injury Severity Score on Impact with intervention
.... 14.451 International vs Domestic Flight
.... 14.452 International vs Domestic Flight with comparator
.... 14.453 International vs Domestic Flight with intervention
.... 14.454 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.455 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.456 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.457 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.458 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.459 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.460 Investigator
.... 14.461 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.462 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.463 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.464 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.465 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.466 Jumping from aircraft with empty backpack
.... 14.467 Jumping from aircraft with parachute
.... 14.468 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.469 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.470 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.471 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.472 M11 Report Template Instructions
.... 14.473 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.474 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.475 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.476 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.477 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.478 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.479 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.480 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.481 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.482 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.483 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.484 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.485 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.486 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.488 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.489 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.490 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.491 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.492 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.493 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.494 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.495 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.496 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.497 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.498 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.499 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.500 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.501 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.502 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.503 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.504 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.505 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.506 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.507 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.508 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.509 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.510 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.511 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.512 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.513 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.514 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.515 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.516 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.517 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.518 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.519 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.520 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.521 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.522 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.523 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.524 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.525 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.526 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.527 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.528 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.529 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.530 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.531 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.532 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.533 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.534 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.535 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.536 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.537 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.538 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.539 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.540 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.541 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.542 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.543 Mean Change in Serum Creatinine (NCT03640312)
.... 14.544 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.545 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.546 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.547 Mean Change in Serum Potassium (NCT03640312)
.... 14.548 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.549 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.550 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.551 Mean Change in Serum Sodium (NCT03640312)
.... 14.552 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.553 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.554 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.555 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.556 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.557 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.558 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.559 Mean Systolic Blood Pressure (NCT03640312)
.... 14.560 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.561 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.562 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.563 Median Age of Parachute Intervention Group
.... 14.564 Medication Adherence (NCT03640312)
.... 14.565 Medication Adherence at 12 weeks
.... 14.566 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.567 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.568 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.569 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.570 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.571 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.572 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.573 Mortality at 14 days
.... 14.574 NCT03640312 Eligibility Criteria
.... 14.575 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.576 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.577 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.578 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.579 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.580 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.581 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.582 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.583 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.584 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.585 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.586 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.587 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.588 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.589 NHANES SEQN Respondent Sequence Number
.... 14.590 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.591 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.592 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.593 NT-proBNP Study Data Dictionary
.... 14.594 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.595 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.596 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.597 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.598 Organ support-free days
.... 14.599 Outcome Definition: All-cause mortality
.... 14.600 Outcome Definition: Body weight
.... 14.601 Outcome Definition: Cardiovascular mortality
.... 14.602 Outcome Definition: End-stage kidney disease
.... 14.603 Outcome Definition: Health-related quality of life
.... 14.604 Outcome Definition: Heart failure
.... 14.605 Outcome Definition: Nonfatal myocardial infarction
.... 14.606 Outcome Definition: Nonfatal stroke
.... 14.607 Outcome Definition: Serious hyperglycaemia
.... 14.608 Outcome Definition: Severe gastrointestinal events
.... 14.609 Outcome Importance Rating 100 of All-cause mortality
.... 14.610 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.611 Outcome Importance Rating 5 of New onset depression
.... 14.612 Outcome Importance Rating 5 of Remission of diabetes
.... 14.613 Outcome Importance Rating 5 of Treatment with opioids
.... 14.614 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.615 Outcome Measure List for QUARTET USA Trial
.... 14.616 Outcome Measure Report for QUARTET USA Trial
.... 14.617 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.618 Outcome Measures Report for NCT03640312
.... 14.619 Outcome Variables List for PARACHUTE Trial
.... 14.620 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.621 Outcome: Death or Major Traumatic Injury on Impact
.... 14.622 Outcome: Injury Severity Score 30 days after Impact
.... 14.623 Outcome: Injury Severity Score on Impact
.... 14.624 OutcomeDefinition: Injury Severity Score on Impact
.... 14.625 OutcomeDefinition: All-cause mortality
.... 14.626 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.627 OutcomeDefinition: Body weight
.... 14.628 OutcomeDefinition: Cardiovascular mortality
.... 14.629 OutcomeDefinition: Diabetes in remission
.... 14.630 OutcomeDefinition: Diabetic ketoacidosis
.... 14.631 OutcomeDefinition: End-stage kidney disease
.... 14.632 OutcomeDefinition: Genital infection
.... 14.633 OutcomeDefinition: HbA1c at 12 months
.... 14.634 OutcomeDefinition: HbA1c at 24 months
.... 14.635 OutcomeDefinition: HbA1c at 36 months
.... 14.636 OutcomeDefinition: HbA1c at 6 months
.... 14.637 OutcomeDefinition: HbA1c at 60 months
.... 14.638 OutcomeDefinition: Health-related quality of life
.... 14.639 OutcomeDefinition: Heart failure
.... 14.640 OutcomeDefinition: Mortality at 14 days
.... 14.641 OutcomeDefinition: New onset depression
.... 14.642 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.643 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.644 OutcomeDefinition: Nonfatal stroke
.... 14.645 OutcomeDefinition: Serious hyperglycaemia
.... 14.646 OutcomeDefinition: Severe gastrointestinal events
.... 14.647 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.648 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.649 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.650 OutcomeVariable: HbA1c at 12 months
.... 14.651 OutcomeVariable: HbA1c at 24 months
.... 14.652 OutcomeVariable: HbA1c at 36 months
.... 14.653 OutcomeVariable: HbA1c at 6 months
.... 14.654 OutcomeVariable: HbA1c at 60 months
.... 14.655 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.656 OutcomeVariable: New onset depression
.... 14.657 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.658 OutcomeVariable: Remission of diabetes
.... 14.659 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.660 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.661 OutcomeVariable_All_cause_mortality
.... 14.662 OutcomeVariable_Treatment_with_opioids
.... 14.663 PARACHUTE Trial baseline characteristics
.... 14.664 PARACHUTE Trial non participants
.... 14.665 PARACHUTE trial participant flow report
.... 14.666 PARACHUTE Trial Participants
.... 14.667 PARACHUTE Trial Participants assigned an empty backpack
.... 14.668 PARACHUTE trial participants assigned parachute
.... 14.669 PARACHUTE Trial Participants available for randomization
.... 14.670 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.671 PARACHUTE Trial Participants randomized into groups
.... 14.672 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.673 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.674 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.675 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.676 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.677 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.678 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.679 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.680 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.681 PARACHUTE Trial Participants that declined randomization
.... 14.682 PARACHUTE Trial Participants with no contact at 30 days
.... 14.683 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.684 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.685 PARACHUTE Trial Results
.... 14.686 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.687 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.688 Participant Flow Report for NCT03640312
.... 14.689 Participant Flow Report for QUARTET USA Trial
.... 14.690 Participant Flow Variables List for PARACHUTE Trial
.... 14.691 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.692 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.693 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.694 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.695 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.696 ParticipantFlowMeasure: Exclusion from analysis
.... 14.697 ParticipantFlowMeasure: Inclusion in analysis
.... 14.698 Participants Excluded from PARACHUTE Study
.... 14.699 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.700 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.701 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.702 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.703 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.704 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.705 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.706 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.707 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.708 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.709 Placebo
.... 14.710 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.711 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.712 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.713 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.714 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.715 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.716 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.717 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.718 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.719 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.720 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.721 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.722 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.723 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.724 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.725 Quadpill once daily
.... 14.726 QUARTET USA Trial Control Group
.... 14.727 QUARTET USA Trial Quadpill group
.... 14.728 randomized into groups for PARACHUTE Trial
.... 14.729 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.730 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.731 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.732 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.733 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.734 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.735 Reasons for exclusion from QUARTET USA Trial
.... 14.736 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.737 Recommendation Justification Code System
.... 14.738 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.739 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.740 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.741 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.742 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.743 Remdesivir
.... 14.744 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.745 Results Section for NCT03640312
.... 14.746 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.747 Risk of Bias Assessment of PARACHUTE trial
.... 14.748 Risk Of Bias Type Value Set
.... 14.749 Screened Group PARACHUTE Trial
.... 14.750 Search Strategy for NMA_Diabetes
.... 14.751 SearchResults: PubMed search for Wonder Woman
.... 14.752 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.753 SearchStrategy: PubMed search for Wonder Woman
.... 14.754 Sex
.... 14.755 Sex with comparator
.... 14.756 Sex with intervention
.... 14.757 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.758 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.759 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.760 Spanish or English Value Set
.... 14.761 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.762 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.763 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.764 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.765 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.766 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.767 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.768 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.769 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.770 Summary of Findings - QUARTET USA Trial
.... 14.771 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.772 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.773 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.774 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.775 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.776 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.777 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.778 Systolic blood pressure at 12 weeks
.... 14.779 Time to integration of results in a recommendation
.... 14.780 VariableDefinition: Comparator
.... 14.781 VariableDefinition: Condition(s)
.... 14.782 VariableDefinition: Date of birth
.... 14.783 VariableDefinition: Date of measurement
.... 14.784 VariableDefinition: Gender
.... 14.785 VariableDefinition: NTproBNP
.... 14.786 VariableDefinition: Unit
.... 14.787 Velocity
.... 14.788 Velocity comparing intervention vs. comparator
.... 14.789 Velocity for enrolled group
.... 14.790 Velocity for non participant group
.... 14.791 Velocity with comparator
.... 14.792 Velocity with intervention
.... 14.793 WebPageCitation: A HEvKA Update Summary
.... 14.794 Weight
.... 14.795 Weight with comparator
.... 14.796 Weight with intervention